{"schema_version":"secwatch.filing_event.v1","accession":"0001628945-24-000005","form_type":"8-K","ticker":null,"cik":"0001628945","company_name":"Cue Health Inc.","filed_at":"2024-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.864036+00:00","generated_at":"2026-06-07T03:08:05.685672+00:00","sec_items":["2.05","8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cue Health lays off 13% of workforce; FDA rejects priority review for Flu+COVID test","bullets":["Workforce reduction of 94 employees (~13% global workforce) as part of new cost reduction plan.","Estimated restructuring charges of $2.1M-$2.8M cash plus $0.1M non-cash stock-based.","FDA on Dec 28, 2023 declined to issue EUA for Flu A/B + COVID-19 molecular test; review not a priority.","FDA cites significant issues, COVID-19 testing landscape, and resource constraints; future EUA submission not precluded."],"urls":{"canonical":"https://secwatch.observer/filing/0001628945-24-000005","json":"https://secwatch.observer/filing/0001628945-24-000005.json","markdown":"https://secwatch.observer/filing/0001628945-24-000005.md","text":"https://secwatch.observer/filing/0001628945-24-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628945/000162894524000005/0001628945-24-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628945/000162894524000005/hlth-20240104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:08:05.685672+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"46e19d20048c907ad0e15273dc752f30eda73572","claim":"Cue Health Inc. announced a restructuring with charges of approximately $2.1 million to $2.8 million (94 employees).","evidence_excerpt":"In connection with the CRP, the Company estimates that it will record an aggregate restructuring charge related to one-time termination benefits in the range of approximately $2.1 million to $2.8 million. The substantial majority of these charges will result in cash expenditures. Cash expenditures in connection with the CRP consist of payments for salary,","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628945/000162894524000005/0001628945-24-000005-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $2.1 million to $2.8 million"},{"label":"Headcount","value":"94 employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}